Comprehensive ReviewComprehensive Symptom Management in Patients with Advanced-Stage Non–Small-Cell Lung Cancer
References (116)
Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer
J Pain Symptom Manage
(1995)Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group
J Pain Symptom Manage
(1996)- et al.
Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer
J Pain Symptom Manage
(2001) - et al.
The frequency and correlates of dyspnea in patients with advanced cancer
J Pain Symptom Manage
(2000) - et al.
Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer
J Pain Symptom Manage
(2002) - et al.
Dyspnea in the advanced cancer patient
J Pain Symptom Manage
(1998) - et al.
The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial
Ann Oncol
(1999) - et al.
How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial
J Pain Symptom Manage
(1999) - et al.
Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study
J Pain Symptom Manage
(2005) - et al.
Nebulized fentanyl citrate improves patients' perception of breathing, respiratory rate, and oxygen saturation in dyspnea
J Pain Symptom Manage
(2002)
Nebulized opioids use in COPD
Chest
Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease
Chest
Cough in cancer patients
Pulm Pharmacol Ther
Correlation between physical performance and fatigue in cancer patients
Ann Oncol
Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer
J Pain Symptom Manage
Fatigue in ambulatory patients with advanced lung cancer: prevalence, correlated factors, and screening
J Pain Symptom Manage
Assessment and management of cancer- related fatigue in adults
Lancet
Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer
J Pain Symptom Manage
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group
Am J Med
Control of common, non-pain cancer symptoms
Semin Oncol
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
J Pain Symptom Manage
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
N Engl J Med
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Group (ECOG) trial - E4599
J Clin Oncol
Erlotinib in previously treated non-small-cell lung cancer
N Engl J Med
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
N Engl J Med
Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party
Br J Cancer
Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital
J Palliat Med
Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data
J Clin Oncol
The experience of breathlessness in lung cancer
Eur J Cancer Care (Engl)
The measurement of breathlessness induced in normal subjects: validity of two scaling techniques
Clin Sci (Lond)
Management of dyspnea
J Support Oncol
Opioids, respiratory function, and dyspnea
Am J Hosp Palliat Care
Subcutaneous morphine for dyspnea in cancer patients
Ann Intern Med
Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea
BMJ
Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide
Clin Sci (Lond)
Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers
Br Med J (Clin Res Ed)
Oxygen or air for palliation of breathlessness in advanced cancer
J R Soc Med
A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea
Palliat Med
The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease
Am Rev Respir Dis
Cold facial stimulation reduces breathlessness induced in normal subjects
Am Rev Respir Dis
Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer
Palliat Med
Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer
BMJ
Non-pharmacological intervention for breathlessness in lung cancer
Palliat Med
Development of a clinical practice guideline for palliative sedation
J Palliat Med
Hydrocodone for cough in advanced cancer
Am J Hosp Palliat Care
Benzonatate for opioid-resistant cough in advanced cancer
Palliat Med
Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients
Br J Cancer
Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care
Palliat Med
The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals
Cancer Nursing
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition
Semin Hematol
Cited by (61)
Moxibustion for chemotherapy-induced myelosuppression: A systematic review and meta-analysis
2023, European Journal of Integrative MedicineConcomitant use of analgesics and immune checkpoint inhibitors in non-small cell lung cancer: A pharmacodynamics perspective
2021, European Journal of PharmacologyHealth-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
2017, The Lancet OncologyCitation Excerpt :Taken together, the superior survival, manageable safety profile, and favourable patient-reported outcome data obtained in the KEYNOTE-024 study suggest that pembrolizumab could be considered as a new standard of care for the first-line treatment of strongly PD-L1-expressing (tumour proportion score of 50% or more), advanced NSCLC. Patients with advanced NSCLC have a high burden of symptoms, such as fatigue, cough, dyspnoea, anorexia, weight loss, and pain that can have a substantial negative effect on health-related quality of life (HRQOL) and functioning.2–5 Therefore, the effect of novel treatments on symptom control and HRQOL needs to be considered alongside survival.
The role of advanced nursing in lung cancer: A framework based development
2015, European Journal of Oncology NursingCitation Excerpt :The systemic therapy is nearly always proposed to lung cancer patients. Further, as lung cancer is often detected in advanced stages, these patients often need high levels of supportive care (Joyce et al., 2008; Temel et al., 2006). Therefore, we focused on developing an APLCN clinical pathway for lung cancer patients receiving systemic therapy combined (or not) with radiotherapy.
Perceptions of health status and survival in patients with metastatic lung cancer
2014, Journal of Pain and Symptom Management
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.